What happened

Joseph Shulman, chief technical officer of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), sold 45,921 common shares, reducing Shulman's direct stake. The Nov. 18 sale exceeded the shares Shulman acquired through option exercises that day, leaving Shulman with less common stock than before the exercises.

The sale brought in $5.51 million before the cost of exercising the options. Shulman sold the shares in multiple transactions at a weighted average of $119.90 per share, with prices ranging from $119.75 to $120.36 per share.

Shulman exercised options from four grants, all at prices below the sale range. The Feb. 9, 2022 grant yielded 1,961 shares at $6.80 each, and the Feb. 1, 2023 grant yielded 4,188 shares at $27.35 each. The Feb. 16, 2024 grant yielded 24,944 shares at $49.23 each, and the Feb. 14, 2025 grant yielded 9,374 shares at $56.69 each.

Why it matters

By OptimistFi's calculation, the sale represented 81.4% of the 56,382 common shares Shulman held after exercising the options that day. The sale left Shulman with 10,461 common shares held directly. Both the exercises and the sales followed a Rule 10b5-1 trading plan Shulman adopted on Dec. 15, 2025.

Shulman's remaining equity exposure also included options from all four grants. The remaining options cover 3,984 shares through 2032 and 8,375 shares through 2033. The later grants carry options on 25,306 shares expiring in 2034 and 28,126 shares expiring in 2035.

The grants tie vesting to continued service. Each grant vests in 16 roughly equal installments, with each installment tied to another three full months of service after the grant date.

The sale leaves OptimistFi's view unchanged. The investment question is whether Rhythm Pharmaceuticals can sustain high gross margins as it builds durable revenue and works toward profitability.

Explain the financial terms

A Rule 10b5-1 plan is a trading plan an insider sets up in advance, while not holding inside information, that schedules later trades.

What's next

Rhythm Pharmaceuticals' next quarterly report is the next test of whether the company can grow revenue while sustaining its gross margins.

Sources checked automatically Nov 21, 2026 · Human review: none
Thesis impactRYTM: no published thesis yet.